Nurix Therapeutics Inc to Announce Strategic Collaboration with Seagen Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory Renza - RBC Capital Markets - Analyst : Hi. This is support for Gregory. I was wondering if you can speak a little bit more about if there are certain and cancer indications that might be more attractive for DAC? And are you thinking about -- more of a traditional cancer targets or ADC is open doors to potentially newer classes of cancer target? Thank you.

Question: Gregory Renza - RBC Capital Markets - Analyst : And if I may ask -- just another question. I'm just curious -- what could we expect in terms of the therapeutic windows for DAC as opposed to traditional ADCs and yield? You also expect the same levels of bystander effect? Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 07, 2023 / 12:30PM, NRIX.OQ - Nurix Therapeutics Inc to Announce Strategic Collaboration with Seagen

Question: Gregory Renza - RBC Capital Markets - Analyst : Thank you so much.

Question: Joel Beatty - Robert W. Baird & Co., Inc. - Analyst : Hi. Congrats on the deal and thanks for taking the questions. With the pending partnership of Seagen and Pfizer, is this a collaboration that was reviewed by Pfizer at all, or did they have input into this?

Question: Joel Beatty - Robert W. Baird & Co., Inc. - Analyst : Great. And then with the agreement with Seagen, does Seagen have the right to veto Nurix opting in on a target similar to the way it's laid out in the Gilead agreement?

Question: Joel Beatty - Robert W. Baird & Co., Inc. - Analyst : Great. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 07, 2023 / 12:30PM, NRIX.OQ - Nurix Therapeutics Inc to Announce Strategic Collaboration with Seagen

Question: Willey Stephen - Stifel Financial Corp. - Analyst : Yeah, good morning. Thanks for my questions.

Question: Willey Stephen - Stifel Financial Corp. - Analyst : So this sounds like a pretty interesting concept, but I guess, can you speak to some of the work that you've done thus far just to establish technical proof of concept?

Question: Willey Stephen - Stifel Financial Corp. - Analyst : Okay. That's helpful. And maybe a bit of a naive question, but presumably with an antibody scaffold, you can leverage less frequent dosing. And I guess, I'm kind of wondering if you need to tweak the PK profile of the degrader that you're delivering in order to accommodate the re synthesis rate of target protein? And then you talked about the multiplicity feature here, I guess being able to use the same degrader across multiple different antibody scaffolds, but I'm guessing that the re synthesis rates for some of these target proteins are probably different across different target tissues and organs. So I guess I'm just trying to think about the degrader part of this, the pharmacology, and then how that ties into less frequent dosing?

Question: Willey Stephen - Stifel Financial Corp. - Analyst : Okay. And then just on the multiplicity side, I guess it's just that, again, another naive question, but do you typically see pretty distinct re synthesis rates of the same protein within different target tissues?

Question: Willey Stephen - Stifel Financial Corp. - Analyst : Okay. Thanks for taking the questions and congrats.

Question: Eric Joseph - JP Morgan Chase & Co. - Analyst : Yeah. Good morning. Thanks for taking the questions. Just to clarify, are there specific targets or cell antigens that are predefined under the collaboration agreement with Seagen? And I could see how the DAC approach could be an end run around the limited bioavailability for some TPD chemistry. That said, are you precluded from developing an oral degrader for any target within the Seagen collaboration if you are sort of able to innovate around any bioavailability issues?

Question: Eric Joseph - JP Morgan Chase & Co. - Analyst : Okay, great. And I know it's super early stage with the announcement here. I guess is there a general sense of when a first development candidate might be nominated? I guess how far out should we be thinking on that front?

Question: Eric Joseph - JP Morgan Chase & Co. - Analyst : Okay, great. If I could maybe just one quick question on the proprietary pipeline. Any updates regarding regulatory actions for [21/27] to provide on this call or what you might narrow -- are you narrowing guidance at all as to when you might be updating investors on that front?

Question: Eric Joseph - JP Morgan Chase & Co. - Analyst : Okay, great. Thanks very much. Thanks for taking the questions.

Question: Gil Blum - Needham & Company LLC - Analyst : Hey, good morning, everyone, and thanks for taking our questions. So generally, use of ADCs improves the therapeutic window. From maybe a different way of asking questions that was asked here before, does this provide you access and the ability to maybe look at protein degrader previously wouldn't have because the target is essential?

Question: Gil Blum - Needham & Company LLC - Analyst : Great. And maybe another topic that was touched upon a little bit also in your own presentation. So it feels like there's potential here to overcome certain resistance mechanisms that are typical for some of our other agents, both through the differences of PK/PD and the fact that the protein degraders remove a protein. I'd love to hear your thoughts on that.

Question: Gil Blum - Needham & Company LLC - Analyst : All right. Thanks for taking our questions and let me also add my congratulations.

Question: Peter Lawson - Barclays US LLC - Analyst : Thanks for taking on the questions. I guess just around IP protection, is there anything that we should be thinking about that can hinder other degrader of ADC companies from entering the space? And then I have a question about toxicities and your thoughts if they could be a potential drug class toxicities for these DAC?

Question: Peter Lawson - Barclays US LLC - Analyst : And then just a final question, it touches on the prior questions of whether the delivery of the degrader, fiber, antibody, and through the endosome, and the conjugation itself, does that changes that level of degradation and the speed of activity of the degrader?

Question: Joe Catanzaro - Piper Sandler Companies - Analyst : Hey, everybody, thanks for taking my questions and congrats on the deal. I guess maybe a couple of follow-ups on some things that have already been discussed. First, Gwenn, I know you mentioned potentially more chemicals flexibility, but just wondering if there's any other specific different considerations around degrader design when thinking about potential conjugation, obviously, relative to what you've done with bare degraders. I guess I'm thinking whether a conjugation needs to be incorporated and how that impacts the screening process? But any additional thoughts there would be appreciated. Thanks.

Question: Joe Catanzaro - Piper Sandler Companies - Analyst : Thanks. And then maybe my second quick question, I guess a follow-up on the PK/PD discussion, but just a little bit different. I know with traditional ADCs, there's usually like a hit to pharmacokinetics as you conjugate more payload. So just any thoughts around how many degraders you think you could potentially conjugate and still maintain favorable PK properties? Thanks.

Question: Joe Catanzaro - Piper Sandler Companies - Analyst : Okay, got it. I appreciate your thoughts and thanks for taking my questions.